TY  - JOUR
AU  - Sopić, Miron
AU  - Karaduzovic-Hadziabdic, Kanita
AU  - Kardassis, Dimitris
AU  - Maegdefessel, Lars
AU  - Martelli, Fabio
AU  - Meerson, Ari
AU  - Munjas, Jelena
AU  - Niculescu, Loredan S.
AU  - Stoll, Monika
AU  - Magni, Paolo
AU  - Devaux, Yvan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5616
AB  - Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.
PB  - Elsevier Ltd.
T2  - Journal of Molecular and Cellular Cardiology Plus
T1  - Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges
VL  - 6
SP  - 100048
DO  - 10.1016/j.jmccpl.2023.100048
ER  - 

@article{
author = "Sopić, Miron and Karaduzovic-Hadziabdic, Kanita and Kardassis, Dimitris and Maegdefessel, Lars and Martelli, Fabio and Meerson, Ari and Munjas, Jelena and Niculescu, Loredan S. and Stoll, Monika and Magni, Paolo and Devaux, Yvan",
year = "2023",
abstract = "Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.",
publisher = "Elsevier Ltd.",
journal = "Journal of Molecular and Cellular Cardiology Plus",
title = "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges",
volume = "6",
pages = "100048",
doi = "10.1016/j.jmccpl.2023.100048"
}

Sopić, M., Karaduzovic-Hadziabdic, K., Kardassis, D., Maegdefessel, L., Martelli, F., Meerson, A., Munjas, J., Niculescu, L. S., Stoll, M., Magni, P.,& Devaux, Y.. (2023). Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus
Elsevier Ltd.., 6, 100048.
https://doi.org/10.1016/j.jmccpl.2023.100048

Sopić M, Karaduzovic-Hadziabdic K, Kardassis D, Maegdefessel L, Martelli F, Meerson A, Munjas J, Niculescu LS, Stoll M, Magni P, Devaux Y. Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus. 2023;6:100048.
doi:10.1016/j.jmccpl.2023.100048 .

Sopić, Miron, Karaduzovic-Hadziabdic, Kanita, Kardassis, Dimitris, Maegdefessel, Lars, Martelli, Fabio, Meerson, Ari, Munjas, Jelena, Niculescu, Loredan S., Stoll, Monika, Magni, Paolo, Devaux, Yvan, "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges" in Journal of Molecular and Cellular Cardiology Plus, 6 (2023):100048,
https://doi.org/10.1016/j.jmccpl.2023.100048 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Vilne, Baiba
AU  - Gerdts, Eva
AU  - Trindade, Fábio
AU  - Uchida, Shizuka
AU  - Khatib, Soliman
AU  - Wettinger, Stephanie Bezzina
AU  - Devaux, Yvan
AU  - Magni, Paolo
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5145
AB  - Multiomics studies offer accurate preventive and therapeutic strategies for atherosclerotic cardiovascular disease (ASCVD) beyond traditional risk factors. By using artificial intelligence (AI) and machine learning (ML) approaches, it is possible to integrate multiple ‘omics and clinical data sets into tools that can be utilized for the development of personalized diagnostic and therapeutic approaches. However, currently multiple challenges in data quality, integration, and privacy still need to be addressed. In this opinion, we emphasize that joined efforts, exemplified by the AtheroNET COST Action, have a pivotal role in overcoming the challenges to advance multiomics approaches in ASCVD research, with the aim to foster more precise and effective patient care.
PB  - Elsevier Ltd
T2  - Trends in Molecular Medicine
T1  - Multiomics tools for improved atherosclerotic cardiovascular disease management
VL  - 29
IS  - 12
SP  - 983
EP  - 995
DO  - 10.1016/j.molmed.2023.09.004
ER  - 

@article{
author = "Sopić, Miron and Vilne, Baiba and Gerdts, Eva and Trindade, Fábio and Uchida, Shizuka and Khatib, Soliman and Wettinger, Stephanie Bezzina and Devaux, Yvan and Magni, Paolo",
year = "2023",
abstract = "Multiomics studies offer accurate preventive and therapeutic strategies for atherosclerotic cardiovascular disease (ASCVD) beyond traditional risk factors. By using artificial intelligence (AI) and machine learning (ML) approaches, it is possible to integrate multiple ‘omics and clinical data sets into tools that can be utilized for the development of personalized diagnostic and therapeutic approaches. However, currently multiple challenges in data quality, integration, and privacy still need to be addressed. In this opinion, we emphasize that joined efforts, exemplified by the AtheroNET COST Action, have a pivotal role in overcoming the challenges to advance multiomics approaches in ASCVD research, with the aim to foster more precise and effective patient care.",
publisher = "Elsevier Ltd",
journal = "Trends in Molecular Medicine",
title = "Multiomics tools for improved atherosclerotic cardiovascular disease management",
volume = "29",
number = "12",
pages = "983-995",
doi = "10.1016/j.molmed.2023.09.004"
}

Sopić, M., Vilne, B., Gerdts, E., Trindade, F., Uchida, S., Khatib, S., Wettinger, S. B., Devaux, Y.,& Magni, P.. (2023). Multiomics tools for improved atherosclerotic cardiovascular disease management. in Trends in Molecular Medicine
Elsevier Ltd., 29(12), 983-995.
https://doi.org/10.1016/j.molmed.2023.09.004

Sopić M, Vilne B, Gerdts E, Trindade F, Uchida S, Khatib S, Wettinger SB, Devaux Y, Magni P. Multiomics tools for improved atherosclerotic cardiovascular disease management. in Trends in Molecular Medicine. 2023;29(12):983-995.
doi:10.1016/j.molmed.2023.09.004 .

Sopić, Miron, Vilne, Baiba, Gerdts, Eva, Trindade, Fábio, Uchida, Shizuka, Khatib, Soliman, Wettinger, Stephanie Bezzina, Devaux, Yvan, Magni, Paolo, "Multiomics tools for improved atherosclerotic cardiovascular disease management" in Trends in Molecular Medicine, 29, no. 12 (2023):983-995,
https://doi.org/10.1016/j.molmed.2023.09.004 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Kararigas, Georgios
AU  - Devaux, Yvan
AU  - Magni, Paolo
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4916
PB  - Oxford University Press
T2  - European heart journal
T1  - Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research
VL  - 44
IS  - 24
SP  - 2143
EP  - 2145
DO  - 10.1093/eurheartj/ehad153
ER  - 

@article{
author = "Sopić, Miron and Kararigas, Georgios and Devaux, Yvan and Magni, Paolo",
year = "2023",
publisher = "Oxford University Press",
journal = "European heart journal",
title = "Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research",
volume = "44",
number = "24",
pages = "2143-2145",
doi = "10.1093/eurheartj/ehad153"
}

Sopić, M., Kararigas, G., Devaux, Y.,& Magni, P.. (2023). Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research. in European heart journal
Oxford University Press., 44(24), 2143-2145.
https://doi.org/10.1093/eurheartj/ehad153

Sopić M, Kararigas G, Devaux Y, Magni P. Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research. in European heart journal. 2023;44(24):2143-2145.
doi:10.1093/eurheartj/ehad153 .

Sopić, Miron, Kararigas, Georgios, Devaux, Yvan, Magni, Paolo, "Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research" in European heart journal, 44, no. 24 (2023):2143-2145,
https://doi.org/10.1093/eurheartj/ehad153 . .